DipernA

DipernA is a preclinical-stage biotechnology company focused on the development of next-generation mRNA therapeutics. Founded by Jim DiPerna, the former Chief Technical Officer of Nutcracker Therapeutics, the company utilizes a proprietary platform designed to optimize mRNA translation efficiency and tissue-specific expression. By engineering mRNA molecules to maximize protein production in target cells while minimizing off-target expression, DipernA aims to overcome the potency and safety limitations of existing mRNA platforms. The company is currently advancing a pipeline of precision mRNA medicines for high-unmet-need indications across metabolic, oncology, and rare disease areas.